GV-196771A is primarily investigated for its potential therapeutic applications, particularly in the field of neuroscience and pain management. It acts as a selective antagonist for the glycine site on the NMDA receptor, which plays a crucial role in modulating excitatory neurotransmission in the central nervous system. By blocking this site, GV-196771A may help reduce neuropathic pain and other conditions associated with overactivation of NMDA receptors, such as chronic pain syndromes and certain neurodegenerative disorders. Its application is being explored in preclinical and clinical studies to assess its efficacy and safety in treating these conditions. Additionally, it may have implications in research aimed at understanding the mechanisms of NMDA receptor function and its involvement in various neurological diseases.